Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Anti-VEGF therapy enhances mechanical barriers to therapy in colorectal cancer liver metastases by increasing hyaluronan deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence indicates that high-dose and/or long-term antiangiogenic therapy causes massive vessel pruning and increases immunosuppression in tumour models37–40”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that an optimum level of VEGF and ANG2 blockade will be needed to alleviate immunosuppression in the TME”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Experimental data indicate that VEGF and ANG2 might cooperate to induce tumour immunosuppression and that this effect might be dependent on the relative levels of these cytokines in the TME35–37”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results suggest that high-dose anti-VEGF therapy limits the benefits of chemotherapy in mouse models and in patients with metastatic colorectal cancer (CRC) or advanced-stage NSCLC37,70,71”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High doses of anti-VEGF agents can also lead to increased deposition of extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumour immune cells, such as monocytic and granulocytic MDSCs37–39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [37]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“Several mechanisms of resistance to antiangiogenic therapy have been proposed thus far (9, 33).”
BackgroundSelf-citationAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Woessner, J. F. (1961) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(61)90291-0 · Cited by 3,840 · cited 1×
“Total collagen content was determined by measuring hydroxyproline content of the hydrolysate samples (76).”
MethodDelivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Self-citationTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Identification of splenic reservoir monocytes and their deployment to inflammatory sites
Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.-L., Kohler, R. H., Chudnovskiy, A., Waterman, P., et al. (2009) · Science · doi:10.1126/science.1175202 · Cited by 2,221
Research works printed but not linked: 1
- 10.1056/NEJM198612253152606 · DOI · Paper page
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationExtracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
Nia, H. T., Munn, L. L., & Jain, R. K. (2020) · Science · doi:10.1126/science.aaz0868 · Cited by 855
“Stiffening promotes tumor progression in many tumor types, including breast (80, 90), pancreatic (85, 91), colorectal (92), andbrain (93).”
BackgroundSelf-citationThe role of collagen in cancer: from bench to bedside
Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., Zhang, W., Yu, X., & Liu, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2058-1 · Cited by 735
Extracellular matrix (ECM) stiffness and degradation as cancer drivers
Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27681 · Cited by 715
“It seems that reduction of the amount of HA accumulated in the core of ECM stiffness could be a beneficial strategy for decreasing physical obstacles to systemic chemotherapy for patients with cancer.(27) Stiffness‐mediated drug impedance is carried out through directing multiple ways.”
BackgroundConsensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P., Alitalo, K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., van Beijnum, J. R., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 590
Self-citationGenetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“In addition, the higher stiffness in CRC liver metastases than in primary tumors, acquired through the remodeling of ECMdriven by hypoxia-induced elevation of hyaluronic acid and sulfated glycosaminoglycans (Rahbari et al. 2016), limits perfusion of drug delivery (Shen et al. 2020).”
BackgroundStylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.005 · Cited by 563
Self-citationTsilimigras, D. I., Brodt, P., Clavien, P.-A., Muschel, R. J., D’Angelica, M. I., Endo, I., Parks, R. W., Doyle, M., de Santibañes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 556
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Self-citationNormalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Self-citationModulating extracellular matrix stiffness: A strategic approach to boost cancer immunotherapy
Mai, Z., Lin, Y., Lin, P., Zhao, X., & Cui, L. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06697-4 · Cited by 398
“In metastatic colorectal cancer patients, increased HA and sulfated GAGs (sGAG) following anti-VEGF therapy contribute to enhanced ECM stiffness, creating a physical barrier that hinders drug delivery [19].”
BackgroundThe Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics
Prakash, J., & Shaked, Y. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0002 · Cited by 366
“Indeed, targeting HA with hyaluronidase increased tumor perfusion and improved therapeutic efficacy due to reduced ECM stiffness (80).”
BackgroundBao, Y., Wang, L., Shi, L., Yun, F., Liu, X., Chen, Y., Chen, C., Ren, Y., & Jia, Y. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0162-0 · Cited by 351
Shen, Y., Wang, X., Lu, J., Salfenmoser, M., Wirsik, N. M., Schleussner, N., Imle, A., Freire Valls, A., Radhakrishnan, P., Liang, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.005 · Cited by 339
Engineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
Self-citationVennin, C., Chin, V. T., Warren, S. C., Lucas, M. C., Herrmann, D., Magenau, A., Melenec, P., Walters, S. N., del Monte-Nieto, G., Conway, J. R. W., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8504 · Cited by 267
Self-citationExtracellular matrix stiffness: Mechanisms in tumor progression and therapeutic potential in cancer
Zhang, M., & Zhang, B. (2025) · Experimental Hematology & Oncology · doi:10.1186/s40164-025-00647-2 · Cited by 269
“Several preliminary reports have suggested that the addition of HYAL to chemotherapy regimens can significantly improve efficacy; for example, expression of the wild-type HYAL-1 variant triggers apoptosis in bladder cancer cells by inducing a G2-M phase arrest [124].”
Ludwig, B. S., Kessler, H., Kossatz, S., & Reuning, U. (2021) · Cancers · doi:10.3390/cancers13071711 · Cited by 238
Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer
Vennin, C., Murphy, K. J., Morton, J. P., Cox, T. R., Pajic, M., & Timpson, P. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.280 · Cited by 202
The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy
Klein, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00367 · Cited by 196
Tumor Abnormality-Oriented Nanomedicine Design
Zhou, Q., Xiang, J., Qiu, N., Wang, Y., Piao, Y., Shao, S., Tang, J., Zhou, Z., & Shen, Y. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00062 · Cited by 188
The pro-tumorigenic host response to cancer therapies
Shaked, Y. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0209-6 · Cited by 181
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
Huang, M., Lin, Y., Wang, C., Deng, L., Chen, M., Assaraf, Y. G., Chen, Z.-S., Ye, W., & Zhang, D. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100849 · Cited by 173
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93182 · Cited by 164
“Indeed, the therapeutic dose of bevacizumab currently used in the clinic is often considered as a high dose (69), which is comparable to the dose we used in our study (maximum effective dose).”
MethodSelf-citationReactive oxygen species and colorectal cancer
Lin, S., Li, Y., Zamyatnin, A. A., Werner, J., & Bazhin, A. V. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26356 · Cited by 164
“Besides, the usage of bevacizumab induces the ECM remodeling which promote the drug delivery (Rahbari et al., 2016).”
BackgroundSu, Y., Luo, B., Lu, Y., Wang, D., Yan, J. Y., Zheng, J., Xiao, J. H., Wang, Y., Xue, Z., Yin, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2241 · Cited by 175
“An increasing number of studies have shown that lower doses of single-targeted anti-VEGFA or anti-VEGFR2 drugs may be effective strategies for vascular normalization, whereas higher doses will over-prune the vessels to aggravate hypoxia and accelerate the metastasis of malignant tumors (31 – 33).”
Lai, B. F. L., Lu, R. X. Z., Hu, Y., Davenport Huyer, L., Dou, W., Wang, E. Y., Radulovich, N., Tsao, M. S., Sun, Y., & Radisic, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202000545 · Cited by 142
Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710754114 · Cited by 138
“We monitored tumor growth by using a high-frequency ultrasound imaging system two times a week (Vevo 2100 system, VisualSonic) using a probe with a 40-MHz frequency (MS550S) (3).”
BackgroundMethodInfluentialSelf-citationCastro, B. A., Flanigan, P., Jahangiri, A., Hoffman, D., Chen, W., Kuang, R., De Lay, M., Yagnik, G., Wagner, J. R., Mascharak, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.1 · Cited by 138
High-resolution optoacoustic imaging of tissue responses to vascular-targeted therapies
Haedicke, K., Agemy, L., Omar, M., Berezhnoi, A., Roberts, S. S., Machado, C. M. L., Skubal, M., Nagar, K. K., Hsu, H., Kim, K., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0527-8 · Cited by 144
Galjart, B., Nierop, P. M. H., van der Stok, E. P., van den Braak, R. R. J. C., Höppener, D. J., Daelemans, S., Dirix, L. Y., Verhoef, C. K., Vermeulen, P., & Grünhagen, D. J. (2019) · Angiogenesis · doi:10.1007/s10456-019-09661-5 · Cited by 143
Yong, T., Wei, Z., Gan, L., & Yang, X. (2022) · Advanced Materials · doi:10.1002/adma.202201054 · Cited by 130
Zhao, J., Wang, H., Hsiao, C.-H., Chow, D. S.-L., Koay, E. J., Kang, Y., Wen, X., Huang, Q., Ma, Y., Bankson, J. A., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.014 · Cited by 128
Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation
Li, T., Mao, C., Wang, X., Shi, Y., & Tao, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01733-5 · Cited by 120
“However, a recent study has shown that VEGF also plays an important role in ECM remodeling in metastatic colorectal cancer (mCRC) [268].”
BackgroundInfluentialTumor Vasculatures: A New Target for Cancer Immunotherapy
Liu, Z., Wang, Y., Huang, Y., Kim, B. Y. S., Shan, H., Wu, D., & Jiang, W. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.001 · Cited by 129
Self-citationVascular Normalization: A New Window Opened for Cancer Therapies
Yang, T., Xiao, H., Liu, X., Wang, Z., Zhang, Q., Wei, N., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719836 · Cited by 141
Goedegebuure, R. S. A., de Klerk, L. K., Bass, A. J., Derks, S., & Thijssen, V. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03107 · Cited by 123
Zheng, Y., Zhou, R., Cai, J., Yang, N., Wen, Z., Zhang, Z., Sun, H., Huang, G., Guan, Y., Huang, N., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0025 · Cited by 105
Jurj, A. M., Ionescu, C., Berindan‐Neagoe, I., & Braicu, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02484-1 · Cited by 116
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 108
Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization
Xu, Z., Guo, C., Ye, Q., Shi, Y., Sun, Y., Zhang, J., Huang, J., Huang, Y., Zeng, C., Zhang, X. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26697-8 · Cited by 105
Self-citationParallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
Li, X., Shepard, H. M., Cowell, J. A., Zhao, C., Osgood, R. J., Rosengren, S., Blouw, B., Garrovillo, S. A., Pagel, M. D., Whatcott, C. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3284 · Cited by 99
Quantifying solid stress and elastic energy from excised or in situ tumors
Nia, H. T., Datta, M., Seano, G., Huang, P., Munn, L. L., & Jain, R. K. (2018) · Nature Protocols · doi:10.1038/nprot.2018.020 · Cited by 101
Self-citationCircular RNAs in the tumour microenvironment
Ma, Z., Shuai, Y., Gao, X., Wen, X., & Ji, J. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1113-0 · Cited by 105
“Vascular endothelial growth factor (VEGF), which is amplified in various cancers, has been recognized to be essential for both physiological and pathological angiogenesis [71, 72].”
BackgroundBlocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases
Rachman-Tzemah, C., Zaffryar‐Eilot, S., Grossman, M., Ribero, D., Timaner, M., Mäki, J. M., Myllyharju, J., Bertolini, F., Hershkovitz, D., Sagi, I., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.005 · Cited by 103
“These effects may also explain why, at least pre-clinically, antiangiogenic drugs sometimes promote metastasis (Ebos et al., 2009; Pàez-Ribes et al., 2009; Rahbari et al., 2016).”
BackgroundZhong, M., Chen, Y., Xiao, Y., Xu, L., Zhang, G., Lu, J., Qiu, H., Ge, W., & Wu, B. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.003 · Cited by 99
Ho, W. W., Gomes-Santos, I. L., Aoki, S., Datta, M., Kawaguchi, K., Talele, N. P., Roberge, S., Ren, J. P., Liu, H., Chen, I. X., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105323118 · Cited by 102
Self-citationTherapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 111
“It has been recently noted in human and mouse models of CRC liver metastatization that antiVEGF therapy results in abnormal deposition of proteoglycans, in particular hyaluronic acid and sulfated glycosaminoglycans (Rahbari et al., 2016).”
BackgroundEngineered Bacteria Enhance Immunotherapy and Targeted Therapy through Stromal Remodeling of Tumors
Thomas, S. C., Madaan, T., Kamble, N. S., Siddiqui, N. A., Pauletti, G. M., & Kotagiri, N. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101487 · Cited by 106
Gordon-Weeks, A. N., Lim, S. Y., Yuzhalin, A. E., Lucotti, S., Vermeer, J. A. F., Jones, K. I., Chen, J., & Muschel, R. J. (2019) · Cancers · doi:10.3390/cancers11050630 · Cited by 97
“to ensure that the inhibition of LAMA5 does not inadvertently lead to therapeutic resistance as has been reported for VEGF inhibition in the setting of liver metastasis [40].”
BackgroundNovel Drugs with High Efficacy against Tumor Angiogenesis
Qi, S., Deng, S., Lian, Z., & Yu, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136934 · Cited by 99
Millar, D. G., Ramjiawan, R. R., Kawaguchi, K., Gupta, N., Jiang, C., Zhang, S., Nojiri, T., Ho, W. W., Aoki, S., Jung, K., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0404-8 · Cited by 89
Self-citationLi, J., Wang, Y., Wang, X., & Yang, Q. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01817-8 · Cited by 97
Exploring the Potential of Nanotherapeutics in Targeting Tumor Microenvironment for Cancer Therapy
Muntimadugu, E., Kommineni, N., & Khan, W. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.010 · Cited by 82
Collective cancer invasion forms an integrin-dependent radioresistant niche
Haeger, A., Alexander, S., Vullings, M., Kaiser, F. M. P., Hulsbergen-Veelken, C. A. R., Flucke, U. E., Koehl, G. E., Hirschberg, M., Flentje, M. P., Hoffman, R. M., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181184 · Cited by 91
“, 2014), including hypoxia-related and/or metabolic stress and adhesion signaling (Hirata et al., 2015; Verduzco et al., 2015; Rahbari et al., 2016).”
Zeng, X., Ward, S. E., Zhou, J., & Cheng, A. S. L. (2021) · Cancers · doi:10.3390/cancers13102418 · Cited by 88
“Depletion of HA could reduce the physical barriers to systemic treatments in CRC liver metastases [106].”
BackgroundLi, S., Chen, J. Y., & Sun, Z. (2021) · 癌症:英文版 · doi:10.1002/cac2.12183 · Cited by 87
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
Chen, W., Shen, L., Jiang, J., Zhang, L., Zhang, Z., Pan, J., Ni, C., & Chen, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00312-w · Cited by 79
“High-dose or long-term antiangiogenic therapy causes large-scale vascular pruning in vitro, which aggravates hypoxia or acidosis in the TME and promotes immunosuppression, suggesting that the optimal doses of antiangiogenic drugs need to be further explored [105, 106].”
BackgroundTumor matrix stiffness provides fertile soil for cancer stem cells
Safaei, S., Sajed, R., Shariftabrizi, A., Dorafshan, S., Zanjani, L. S., Manshadi, M. D., Madjd, Z., & Ghods, R. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02992-w · Cited by 83
“In preclinical models, they showed that enzymatic depletion of HA, partially restored perfusion in the liver in metastatic colorectal cancer following chemotherapy and antiVEGF therapy leading to prolonged survival [210].”
BackgroundCarpenter, R., Kwak, J., Peyton, S. R., & Lee, J. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0307-x · Cited by 74
Emerging mechanisms progress of colorectal cancer liver metastasis
Zhao, W., Dai, S., Yue, L., Fan, X., Gu, J. H., Dai, X., & Qian, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1081585 · Cited by 74
“This result may be due to the adverse effects of anti-VEGF drugs on the regular vascular system of the liver, resulting in more fragile and permeable hepatic sinusoidal vessels (106, 107).”
BackgroundThe role of extracellular matrix in angiogenesis: Beyond adhesion and structure
Libby, J. R., Royce, H. A., Walker, S. R., & Li, L. (2024) · Biomaterials and Biosystems · doi:10.1016/j.bbiosy.2024.100097 · Cited by 97
“A recent study by Fukumura and colleagues discovered that VEGF inhibition remodels the ECM in the tumor microenvironment and significantly increases the expression of HA and sGAGs in both mouse models and in patient samples [113].”
BackgroundCancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics
Bighetti‐Trevisan, R. L., Sousa, L. O., CASTILHO, R. M., & Almeida, L. O. (2019) · Stem Cells International · doi:10.1155/2019/9618065 · Cited by 70
“This situation enhanced the stiffness of the liver tumors, compromising intratumor perfusion and leading to a reduction in intratumor delivery of anticancer drugs [128].”
BackgroundMatrix Stiffness and Colorectal Cancer
Liu, C., Pei, H., & Tan, F. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s231010 · Cited by 74
Tan, F., Huang, Y., Pei, Q., Liu, H., Pei, H., & Zhu, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27532 · Cited by 64
Self-citationJeong, J., Suh, Y., & Jung, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01817 · Cited by 60
Self-citationWang, H., Jin, Y., Tan, Y., Zhu, H., Huo, W., Niu, P., Li, Z., Zhang, J., Liang, X., & Yang, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120992 · Cited by 58
Chandra, A., Jahangiri, A., Chen, W., Nguyen, A. T., Yagnik, G., Pereira, M. P., Jain, S., Garcia, J. H., Shah, S. S., Wadhwa, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1305 · Cited by 64
“The first model was hydrogel platforms (23) that model the gray and white matter along which peritumoral invasion occurs and contain the hyaluronic acid (HA) upregulated in bevacizumab-resistant tumor ECM (24).”
BackgroundMethodAdetunji, J. A., Fasae, K. D., Awe, A., Paimo, O. K., Adegoke, A. M., Akintunde, J. K., & Sekhoacha, M. P. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17166 · Cited by 63
Concise Review: An (Im)Penetrable Shield: How the Tumor Microenvironment Protects Cancer Stem Cells
Relation, T., Dominici, M., & Horwitz, E. M. (2017) · Stem Cells · doi:10.1002/stem.2596 · Cited by 60
Zheng, Q., Min, S., & Zhou, Q. (2021) · Bioscience Reports · doi:10.1042/bsr20204370 · Cited by 70
Karlsson, S., & Nyström, H. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103712 · Cited by 60
Gonzalez‐Molina, J., Moyano‐Galceran, L., Single, A., Gultekin, O., Alsalhi, S., & Lehti, K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.012 · Cited by 59
Rada, M., Lazaris, A., Kapelanski‐Lamoureux, A., Mayer, T. Z., & Metrakos, P. P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.001 · Cited by 56
Hyaluronan in liver fibrosis: basic mechanisms, clinical implications, and therapeutic targets
Kim, J., & Seki, E. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000083 · Cited by 66
Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy
Vennin, C., Rath, N., Pajic, M., Olson, M. F., & Timpson, P. (2017) · Small GTPases · doi:10.1080/21541248.2017.1345712 · Cited by 56
“motherapy efficacy and prolonged survival compared with anti-VEGF therapy alone.(52) Our work also indi-”
BackgroundProbing the physical hallmarks of cancer
Nia, H. T., Munn, L. L., & Jain, R. K. (2025) · Nature Methods · doi:10.1038/s41592-024-02564-4 · Cited by 62
“Hyaluronidase also improves treatment efficacy in colorectal liver metastasis when combined with anti-VEGF agents and chemotherapy 23 .”
Self-citationSun, Q., Li, Y., Shen, W. H., Shang, W., Xu, Y., Yang, J., Chen, J., Gao, W., Wu, Q., Xu, F., et al. (2024) · Advanced Materials · doi:10.1002/adma.202310673 · Cited by 60
Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment
Schito, L. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00209.2018 · Cited by 52
“Remarkably, vessel normalization can also enhance CD4 and CD8 T cell infiltration, M1-like macrophage polarization, and the response to adoptive cell transfer immunotherapy in experimental cancers (77, 78, 86, 127, 150), thereby emerging as a potential approach to deliver immunotherapy to the hTME.”
BackgroundHarmonic Motion Imaging of Pancreatic Tumor Stiffness Indicates Disease State and Treatment Response
Payen, T., Oberstein, P. E., Saharkhiz, N., Palermo, C. F., Sastra, S. A., Han, Y., Nabavizadeh, A., Sagalovskiy, I. R., Orelli, B., Rosario, V. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3669 · Cited by 49
“The biomechanical properties of cancerous tissues can be altered in response to chemotherapy, by directly altering the viscoelastic properties of tumor cells (36), through indirect effects on the tumor microenvironment (37), or through tissue decompression following the apoptotic loss of”
BackgroundRole of Extracellular Matrix in Gastrointestinal Cancer-Associated Angiogenesis
Andreuzzi, E., Capuano, A., Poletto, E., Pivetta, E., Fejza, A., Favero, A., Doliana, R., Cannizzaro, R., Spessotto, P., & Mongiat, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103686 · Cited by 49
Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 56
“Anti-VEGFR treatments have been shown to induce hypoxia in the tumor microenvironment (TME), inducing extracellular matrix (ECM) remodeling and overexpression of hyaluronic acid in colorectal liver metastasis mouse models, conferring resistance to anti-VEGF therapy (82).”
Yamamoto, S., Kato, A., Sakurai, Y., Hada, T., & Harashima, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.010 · Cited by 46
“Likewise, a recent study showed that an anti-VEGF antibody treatment resulted in increased levels of glycosaminoglycans (GAGs) [57].”
BackgroundHypoxia: Turning vessels into vassals of cancer immunotolerance
Schito, L., & Rey, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.015 · Cited by 49
Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy
Li, S., Zhang, Q., & Hong, Y. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820980116 · Cited by 54
Periostin Limits Tumor Response to VEGFA Inhibition
Keklikoglou, I., Kadioglu, E., Bissinger, S., Langlois, B., Bellotti, A., Orend, G., Ries, C. H., & Palma, M. D. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.035 · Cited by 47
Lei, X., Zhong, Y., Huang, L., Li, S., Fu, J., Zhang, L., Zhang, Y., Deng, Q., & Yu, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2425-0 · Cited by 51
Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors
Conway, J. R. W., Warren, S. C., & Timpson, P. (2017) · Methods · doi:10.1016/j.ymeth.2017.04.014 · Cited by 42
“696 Vascular patency is incredibly important for drug delivery [230, 231].”
BackgroundTang, J., Zhang, C., Huang, Y., Wang, L., Xu, Z., Zhang, D., Zhang, Y., Peng, W., Feng, Y., & Sun, Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03565-3 · Cited by 48
Self-citationLiu, B., Liu, T., Liu, Y., Feng, X., Jiang, X., Long, J., Ye, S., Chen, D., Wang, J., & Yang, Z. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.69178 · Cited by 50
“Studies have shown that HA reorganization is strongly associated with ECM remodeling and stiffness [47].”
BackgroundMolecular Targets in Hepatocarcinogenesis and Implications for Therapy
Wu, M., Yiang, G.-T., Cheng, P., Chu, P., & Li, C.-J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080213 · Cited by 45
“Serum VEGF can also be used to deduce patient immune status and indicate tumor metastasis [63,64].”
BackgroundPerspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
Knipper, K., Lyu, S. I., Quaas, A., Bruns, C. J., & Schmidt, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713482 · Cited by 46
“Additional enzymatic depletion of hyaluronic acid could provide prolonged survival under anti-VEGF therapy [102].”
BackgroundHe, Y., Zhan, L., Shi, J., Xiao, M., Zuo, R., Wang, C., Liu, Z., Gong, W., Chen, L., Luo, Y., et al. (2023) · Advanced Science · doi:10.1002/advs.202207650 · Cited by 43
Immunotherapies targeting tumor vasculature: challenges and opportunities
Dianat-Moghadam, H., Nedaeinia, R., Keshavarz, M., Azizi, M., Kazemi, M., & Salehi, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1226360 · Cited by 36
“Prolonging the normalization window also improves the antitumor immune responses by increasing effector T-cell infiltration (54), ECM remodeling (55), and reprogramming of immunosuppressive TME to enhance the therapeutic efficacy of cancer immunotherapies (39, 54), including immune checkpoint blockers (ICBs) by blocki…”
BackgroundHenríquez, J. A., Sleeman, J. P., & Garvalov, B. K. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9930-x · Cited by 39
Clinical Impact of Exosomes in Colorectal Cancer Metastasis
Ghosh, S., Dhar, R., Shivji, G. G., Dey, D., Devi, A., Jha, S. K., Adhikari, M. D., & Gorai, S. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00199 · Cited by 36
Targeting Tumor Physical Microenvironment for Improved Radiotherapy
Wang, J., Han, Y., Li, Y., Zhang, F., Cai, M., Zhang, X., Chen, J., Ji, C., Ma, J., & Xu, F. (2022) · Small Methods · doi:10.1002/smtd.202200570 · Cited by 41
Immune‐mediated ECM depletion improves tumour perfusion and payload delivery
Yeow, Y. L., Kotamraju, V. R., Wang, X., Chopra, M., Azme, N., Wu, J., Schoep, T. D., Delaney, D. S., Feindel, K. W., Li, J., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910923 · Cited by 39
“…delivery of ECM-degrading enzymes such as PEGPH20 (pegylated hyaluronidase) has been used to degrade tumour ECM components for the purpose of enhancing perfusion and access to solid tumours (Guedan et al, 2010; Provenzano et al, 2012; Caruana et al, 2015; Rahbari et al, 2016; Kirtane et al, 2017).”
BackgroundMethod
Metadata
- Authors
- Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., Heishi, T., Martin, J. D., Huang, Y., Maimon, N., Reissfelder, C., Weitz, J., Boucher, Y., Clark, J. W., Grodzinsky, A. J., Duda, D. G., Jain, R. K., & Fukumura, D.
- Affiliations
- Harvard University (US)
- Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
- University Hospital Carl Gustav Carus (DE)
- Department of General, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307, Germany.
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- Fukumura, Dai
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-10-12
- Volume
- 8
- Issue
- 360
- Pages
- 360ra135-360ra135
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5457741
- OpenAlex
- W2530012709
- Cited by
- 258
- References
- 78
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 24 · 2023: 28 · 2022: 37 · 2021: 40 · 2020: 30 · 2019: 21 · 2018: 19 · 2017: 16 · 2016: 3
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- NIH (CA080124, T32DK007191, CA126642, CA197743, CA096915, CA139168, CA159258, CA098706, CA173518)
- American Cancer Society (120733-RSG-11-073-01-TBG)
- German Research Foundation
- Foundation for Science and Technology
- Portuguese Human Potential Operational Program/European Social Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- anti-VEGF therapy, colorectal liver metastases, extracellular matrix remodeling, hyaluronic acid, sulfated glycosaminoglycans, tumor stiffness, tumor hypoxia, bevacizumab, acquired drug resistance, tumor perfusion, combination chemotherapy
- MeSH terms
- Bevacizumab, Antineoplastic Agents, Immunological, Animals, Hypoxia, Biomechanical Phenomena, Extracellular Matrix, Glycosaminoglycans, Humans, Hyaluronic Acid, Liver Neoplasms, Mice, Inbred BALB C, Mice, Inbred C57BL, Colorectal Neoplasms, Drug Resistance, Neoplasm, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Mice, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.